TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.
Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.
News in the classification of WHO 2022 bladder tumors.
Raspollini MR, Comperat EM, Lopez-Beltran A, Montironi R, Cimadamore A, Tsuzuki T, Netto GJ.
Pathologica. 2022 Feb;115(1):32-40. doi: 10.32074/1591-951X-838. Epub 2023 Jan 25.
[Urothelial tumor markers: update].
de Castro F, Rosell D, Agüera LG, Isa W, Sánchez de la Muela P, Robles JE, Zudaire JJ, Berián JM.
Rev Med Univ Navarra. 1990 Jul-Sep;34(3):167-71.
A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.
Guo J, Ma X, Liu D, Wang F, Xia J, Zhang B, Zhao P, Zhong F, Chen L, Long Q, Jiang L, Zhang S, Liao N, Wang J, Wu W, Sun J, Huang M, Cheng Z, Huang G, Zou C.
Drug Resist Updat. 2024 Sep;76:101116. doi: 10.1016/j.drup.2024.101116. Epub 2024 Jul 3.
Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.
Stakhovskyi O, Kobyliak N, Voylenko O, Stakhovskyi E, Ponomarchuk R, Sulaieva O.
Cells. 2022 May 31;11(11):1802. doi: 10.3390/cells11111802.
Single-cell transcriptomic analysis of tumor heterogeneity and intercellular networks in human urothelial carcinoma.
Jin X, Wang Q, Luo F, Pan J, Lu T, Zhao Y, Zhang X, Xiang E, Zhou C, Huang B, Lu G, Chen P, Shao Y.
Chin Med J (Engl). 2023 Mar 20;136(6):690-706. doi: 10.1097/CM9.0000000000002573.
Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma.
Xiong S, Fan J, Huang C, He S, Liang Y, Zhang Q, Guo B, Wu Y, Xia M, Zhao F, Ci W, Zhou L, Gong Y, Li X.
Int J Biol Sci. 2025 Oct 20;21(15):6649-6673. doi: 10.7150/ijbs.114618. eCollection 2025.
[Tumour-stroma interactions in urothelial cancer].
Hatina J, Kripnerová M, Tuková J, Šrámek J, Dvořák P, Pešta M, Dobrá J, Babuška V, Racek J, Sobol M, Philimonenko A, Hozák P, Czuba Z, Schulz WA, Strell C, Grimm S, Jennek S, Friedrich KH.
Urologe A. 2015 Apr;54(4):516-25. doi: 10.1007/s00120-014-3754-3.
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.
Johnson BA 3rd, Parimi V, Kamanda S, Corney DC, Choi W, Hoffman-Censits J, Kates M, McConkey DJ, Hahn NM, Matoso A.
J Pathol Clin Res. 2025 Mar;11(2):e70021. doi: 10.1002/2056-4538.70021.
Blood-based protein biomarkers in bladder urothelial tumors.
López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C.
J Proteomics. 2021 Sep 15;247:104329. doi: 10.1016/j.jprot.2021.104329. Epub 2021 Jul 21.
